肝动脉化疗栓塞联合射频消融治疗中晚期肝癌的效果及安全性分析

Clinical Analysis of Therapeutic Efficacy and Security Analysis of TACE Combined with RFA for Patients with Advanced Liver Cancer

目的:研究肝动脉化疗栓塞(TACE)联合射频消融(RFA)对中晚期肝癌患者的治疗效果及安全性。方法:选取2017年4月-2018年4月在笔者所在医院接受治疗的30例中晚期肝癌患者为研究对象,随机分为两组,对照组行肝动脉化疗栓塞治疗,研究组行肝动脉化疗栓塞治疗后30 d内再行射频消融治疗;以两组治疗后1、3个月的近期疗效、术后血清AFP水平、不良反应为观察指标,考察治疗有效性与安全性。结果:术后3个月,研究组的ORR、DCR显著优于对照组(P<0.05);研究组的AFP水平的转阴率比对照组显著提高(P<0.05);两组患者的不良反应情况比较差异无统计学意义(P>0.05)。结论:TACE联合RFA治疗中晚期肝癌患者具有良好的临床疗效与安全性。

Objective: To explore the clinical effect and safety of transcatheter arterial chemoembolization combined with radiofrequency ablation for the treatment of advanced liver cancer. Method: 30 patients with advanced liver cancer who were treated in our hospital from April 2017 to April 2018 were selected as subjects. Two groups were randomly divided: study group and control group. The control group was treated with transcatheter arterial chemoembolization. After the treatment group was treated with transcatheter arterial chemoembolization, radiofrequency ablation was performed within 30 days. Treatment effect and safety were observed by the short-term efficacy of 1 month and 3 months after treatment, the changes of serum AFP levels in the two groups, and the toxicity and side effects of the two groups. Result: After 3 months the ORR and DCR of the study group were significantly better than the control group(P<0.05). The AFP level of the study group was significantly higher than that of the control group(P<0.05). There was no significant difference in the incidence of toxic and side effects between the two groups. Conclusion: TACE combined with RFA in the treatment of patients with advanced liver cancer had good clinical efficacy and safety.